Holen Sie sich die Stockscreener-App
41.77
0.80%
0.33
Handel nachbörslich:
41.77
Schlusskurs vom Vortag:
$41.44
Offen:
$41.5
24-Stunden-Volumen:
340.24K
Relative Volume:
0.69
Marktkapitalisierung:
$2.08B
Einnahmen:
$499.95M
Nettoeinkommen (Verlust:
$-36.36M
KGV:
-54.25
EPS:
-0.77
Netto-Cashflow:
$24.22M
1W Leistung:
+5.59%
1M Leistung:
+4.79%
6M Leistung:
+32.44%
1J Leistung:
+27.74%
1-Tages-Spanne:
$41.02
$42.08
1-Wochen-Bereich:
$38.68
$42.08
52-Wochen-Spanne:
$28.29
$43.11
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Vergleichen Sie ATRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
41.77 | 2.06B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
592.27 | 210.16B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.71 | 58.51B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
81.02 | 40.19B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
248.21 | 36.37B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
40.43 | 31.30B | 27.43B | 1.27B | 1.01B | 1.5829 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
AtriCure, Inc. (NASDAQ:ATRC) Nasdaq Index Fund Medical Devices - Kalkine Media
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriCl - PharmiWeb.com
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriClip, Hybrid AF Therapy, and cryoICE cryoSPHERE TechnologiesResearchAndMarkets.com - The AI Journal
Liquidity Mapping Around (ATRC) Price Events - Stock Traders Daily
AtriCure (ATRC): Assessing Valuation After First-In-Human PFA/RFA Procedures and Renewed Analyst Optimism - Yahoo Finance
Assessing AtriCure’s Valuation After a 33.4% Rally in 2025 - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year? - sharewise.com
AtriCure (NASDAQ:ATRC) Stock Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
What AtriCure (ATRC)'s First Dual-Energy PFA–RFA Procedures Mean For Shareholders - Sahm
Big Money Moves: Will AtriCure Inc stock benefit from green energy trendsVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Analysts See an Over 26% Upside in AtriCure (ATRC) - Insider Monkey
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
AtriCure price target raised to $48 from $42 at JPMorgan - MSN
AtriCure announces first patients treated with dual energy platform - MSN
Quarterly Recap: What valuation multiples suggest for AtriCure Inc stock - moha.gov.vn
Is AtriCure Inc. stock a buy in volatile marketsShare Buyback & Smart Allocation Stock Tips - Улправда
AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know - Yahoo Finance
Why AtriCure Inc. stock is favored by top institutionsQuarterly Earnings Summary & Safe Investment Capital Preservation Plans - DonanımHaber
Will AtriCure Inc. stock benefit from green energy trends2025 Growth vs Value & AI Powered Market Entry Ideas - DonanımHaber
Canaccord Genuity Reaffirms Their Buy Rating on Atricure (ATRC) - The Globe and Mail
Atrial Fibrillation Market | Global Market Analysis Report2036 - Fact.MR
Will AtriCure Inc. stock benefit from automation2025 Sector Review & Reliable Intraday Trade Plans - DonanımHaber
Will AtriCure Inc. stock continue upward momentum2025 Earnings Surprises & Low Risk Profit Maximizing Plans - DonanımHaber
Understanding the Setup: (ATRC) and Scalable Risk - Stock Traders Daily
How supply chain issues affect AtriCure Inc. stockJuly 2025 Spike Watch & Safe Capital Preservation Plans - Улправда
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference - BioSpace
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way? - 富途牛牛
AtriCure Earnings Notes - Trefis
JP Morgan Raises AtriCure (ATRC) Price Target to $48 | ATRC Stoc - GuruFocus
ATRC FinancialsIncome Statement - Quiver Quantitative
JPMorgan Chase & Co. Boosts AtriCure (NASDAQ:ATRC) Price Target to $48.00 - MarketBeat
AtriCure, Inc. $ATRC Shares Acquired by Squarepoint Ops LLC - MarketBeat
AtriCure (ATRC) Is Up 6.3% After First Dual-Energy PFA–RFA Human Procedures Success - Sahm
AtriCure (ATRC) Is Up 6.3% After Dual Energy PFA–RFA First-in-Human SuccessHas The Bull Case Changed? - Yahoo Finance
Loss Report: What valuation multiples suggest for AtriCure Inc stockJuly 2025 Outlook & Fast Entry Momentum Alerts - moha.gov.vn
AtriCure treats first patients with dual PFA/RF system - MedTech Dive
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform - Finviz
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? - MSN
CEO Carrel Gifts 4,000 Of AtriCure Inc [ATRC] - TradingView — Track All Markets
AtriCure’s Cryoanalgesia Study: A Potential Game-Changer in Post-Operative Pain Management - MSN
AtriCure reports first patients treated with dual-energy PFA, RF platform - MassDevice
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform - 01net
AtriCure, Inc. Announces the First Patients Treated with Novel Dual Energy Platform - marketscreener.com
AtriCure Reports 1st Treatments with Dual Energy RF, PFA System - Medical Product Outsourcing
AtriCure Says First Patients Treated With Dual-Energy Platform - marketscreener.com
AtriCure (ATRC) Introduces Cutting-Edge Dual Energy Platform in Initial Treatments - GuruFocus
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
1.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):